Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 165

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 165
---
708 $166,857 $56,851 34%GOCOVRI40,849 35,657 5,192 15%108,198 93,922 14,276 15%APOKYN10,387 19,867 (9,480)(48)%38,183 53,811 (15,628)(29)%Trokendi XR10,043 15,318 (5,275)(34)%34,037 48,393 (14,356)(30)%Oxtellar XR12,016 29,805 (17,789)(60)%33,851 86,265 (52,414)(61)%ONAPGO6,806 — 6,806 100 %8,410 — 8,410 100 %Other(1)7,025 7,296 (271)(4)%22,138 22,053 85 —%Total net product sales168,542 170,302 (1,760)(1)%468,525 471,301 (2,776)(1)%Collaboration revenue (ZURZUVAE)(2)20,164 — 20,164 100%20,164 — 20,164 100%Royalty, licensing and other revenues3,397 5,387 (1,990)(37)%18,691 16,357 2,334 14%Total revenues$192,103 $175,689 $16,414 9%$507,380 $487,658 $19,722 4%___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

(2) Includes the Company's proportionate share of sales of ZURZUVAE.

Net Product Sales

Net product sales were $168.5 million and $170.3 million for the three months ended September 30, 2025 and 2024, respectively. Net product sales were $468.5 million and $471.3 million for the nine months ended September 30, 2025 and 2024, respectively. The decrease in both periods was primarily due to the decline in net product sales of APOKYN due to lower volume and decline in net product sales of Oxtellar XR and Trokendi XR due to generic erosion, partially